An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women

Chelsea B Polis, Kathryn M Curtis, Philip C Hannaford, Sharon J Phillips, Tsungai Chipato, James N Kiarie, Daniel J Westreich, Petrus S Steyn, Chelsea B Polis, Kathryn M Curtis, Philip C Hannaford, Sharon J Phillips, Tsungai Chipato, James N Kiarie, Daniel J Westreich, Petrus S Steyn

Abstract

Objective and design: Some studies suggest that specific hormonal contraceptive methods [particularly depot medroxyprogesterone acetate (DMPA)] may increase women's HIV acquisition risk. We updated a systematic review to incorporate recent epidemiological data.

Methods: We searched for articles published between 15 January 2014 and 15 January 2016 and hand-searched reference lists. We identified longitudinal studies comparing users of a specific hormonal contraceptive method against either nonusers of hormonal contraception or users of another specific hormonal contraceptive method. We added newly identified studies to those in the previous review, assessed study quality, created forest plots to display results, and conducted a meta-analysis for data on DMPA versus non-use of hormonal contraception.

Results: We identified 10 new reports of which five were considered 'unlikely to inform the primary question'. We focus on the other five reports, along with nine from the previous review, which were considered 'informative but with important limitations'. The preponderance of data for oral contraceptive pills, injectable norethisterone enanthate, and levonorgestrel implants do not suggest an association with HIV acquisition, though data for implants are limited. The new, higher quality studies on DMPA (or nondisaggregated injectables), which had mixed results in terms of statistical significance, had hazard ratios between 1.2 and 1.7, consistent with our meta-analytic estimate for all higher quality studies of hazard ratio 1.4.

Conclusion: Although confounding in these observational data cannot be excluded, new information increases concerns about DMPA and HIV acquisition risk in women. If the association is causal, the magnitude of effect is likely hazard ratio 1.5 or less. Data for other hormonal contraceptive methods, including norethisterone enanthate, are largely reassuring.

Figures

Fig. 1
Fig. 1
Identification of newly included studies.
Fig. 2
Fig. 2
Use of oral contraceptives (versus non-use of hormonal contraception) and HIV acquisition, among 11 studies considered informative but with important limitations.
Fig. 3
Fig. 3
Use of injectables (depot medroxyprogesterone acetate, norethisterone enanthate, or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.
Fig. 4
Fig. 4
Use of depot medroxyprogesterone acetate (or unspecified injectable) versus non-use of hormonal contraception and HIV acquisition, among 12 studies considered informative but with important limitations.
Fig. 5
Fig. 5
Use of norethisterone enanthate versus non-use of hormonal contraception and HIV acquisition, among six studies considered informative but with important limitations.
Fig. 6
Fig. 6
Hormonal contraceptive methods and HIV acquisition in head-to-head studies, among two studies considered informative but with important limitations.

References

    1. Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90:360–390.
    1. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27:105–113.
    1. Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 2016; 387:462–474.
    1. Schelar E, Polis CB, Essam T, Looker KJ, Bruni L, Chrisman CJ, et al. Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products. Contraception 2016; 93:32–43.
    1. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011; 65:302–307.
    1. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79–97.
    1. Achilles SL, Hillier SL. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS 2013; 27 suppl 1:S5–S15.
    1. Hickey M, Marino JL, Tachedjian G. Critical review: mechanisms of HIV transmission in Depo-Provera users: the likely role of hypoestrogenism. J Acquir Immune Defic Syndr 2016; 71:1–7.
    1. Fichorova RN, Chen PL, Morrison CS, Doncel GF, Mendonca K, Kwok C, et al. The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception. MBio 2015; 6:e00221-15.
    1. World Health Organization. Medical eligibility criteria for contraceptive use. 5th edGeneva, Switzerland: World Health Organization; 2015.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
    1. Veritas Health Innovation. Covidence Systematic Review Software. Melbourne, Australia: Veritas Health Innovation; 2015.
    1. Polis CB, Westreich D, Balkus JE, Heffron R. Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS 2013; 27 suppl 1:S35–S43.
    1. Hernan MA. The hazards of hazard ratios. Epidemiology 2010; 21:13–15.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557–560.
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–422.
    1. Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Graham SM, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 2015; 29:1077–1085.
    1. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15:181–189.
    1. Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J. Risk of HIV infection in depot-medroxyprogesterone acetate (DMPA) users: a systematic review and meta-analysis. Issues Law Med 2015; 30:129–139.
    1. Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod 2014; 29:1810–1817.
    1. Dube K, Zango A, van de Wijgert J, Meque I, Ferro JJ, Cumbe F, et al. HIV incidence in a cohort of women at higher risk in Beira, Mozambique: prospective study 2009–2012. PLoS One 2014; 9:e84979.
    1. Feldblum PJ, Enosse S, Dube K, Arnaldo P, Muluana C, Banze R, et al. HIV prevalence and incidence in a cohort of women at higher risk for HIV acquisition in Chokwe, southern Mozambique. PLoS One 2014; 9:e97547.
    1. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS One 2013; 8:e68825.
    1. McKinnon LR, Izulla P, Nagelkerke N, Munyao J, Wanjiru T, Shaw SY, et al. Risk factors for HIV acquisition in a prospective Nairobi-based female sex worker cohort. AIDS Behav 2015; 19:2204–2213.
    1. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015; 12:1–26.
    1. Wall KM, Kilembe W, Vwalika B, Htee KN, Brill I, Chomba E, et al. Hormonal contraception does not increase women's HIV acquisition risk in Zambian discordant couples, 1994–2012. Contraception 2015; 91:480–487.
    1. Byrne EH, Anahtar MN, Cohen KE, Moodley A, Padavattan N, Ismail N, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis 2016; 16:441–448.
    1. Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception 2016; 93:25–31.
    1. Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, et al. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV 2015; 2:e279–287.
    1. Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS 2012; 26:375–380.
    1. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555–2562.
    1. Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, et al. Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. Sex Transm Dis 2007; 34:638–643.
    1. Delany-Moretlwe S, Rees H. Tshireletso study for women's health. Microbicide feasibility study. Protocol. Hillbrow, South Africa: Reproductive Health Research Unit, University of Witwatersrand; 2010.
    1. McGrath N, Chimbwete C, Bennish M, Cassol S, Nunn A. A feasibility study in preparation for phase III microbicide trials in the Hlabisa sub-district, South Africa. 2014; . [Accessed (by Morrison 2015) 16 April 2014].
    1. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sex Transm Dis 2011; 38:316–323.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168–1174.
    1. Morrison CS. Personal communication: subanalysis of previously unpublished data in IPD meta-analysis. 2015.
    1. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771–1777.
    1. Bulterys M, Chao A, Habimana P, Dushimimana A, Nawrocki P, Saah A. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994; 8:1585–1591.
    1. Feldblum PJ, Lie CC, Weaver MA, Van DL, Halpern V, Adeiga A, et al. Baseline factors associated with incident HIV and STI in four microbicide trials. Sex Transm Dis 2010; 37:594–601.
    1. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19–26.
    1. Heffron R, Rees H, Mugo N, Baeten J. Authors’ reply: use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis 2012; 12:510–511.
    1. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12:75–84.
    1. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003; 17:233–240.
    1. Kilmarx PH, Limpakarnjanarat K, Mastro TD, Saisorn S, Kaewkungwal J, Korattana S, et al. HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 1998; 12:1889–1898.
    1. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007; 75:461–467.
    1. Kumwenda NI, Kumwenda J, Kafulafula G, Makanani B, Taulo F, Nkhoma C, et al. HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS 2008; 19:339–341.
    1. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95–102.
    1. Lutalo T, Musoke R, Kong X, Makumbi F, Serwadda D, Nalugoda F, et al. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS 2013; 27 suppl 1:S27–S34.
    1. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013; 27:1001–1009.
    1. Morrison CS, Chen P, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778–1781.
    1. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85–95.
    1. Lavreys L, Baeten JM, Martin HL, Overbaugh J, Mandaliya K, Ndinya-Achola JO, et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 2004; 18:695–697.
    1. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 2012; 26:497–504.
    1. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166–174.
    1. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991; 163:233–239.
    1. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010; 53:606–613.
    1. Saracco A, Musicco M, Nicolosi A, Angarano G, Arici C, Gavazzeni G, et al. Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr 1993; 6:497–502.
    1. Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, et al. Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS 2009; 23:415–422.
    1. Sinei SK, Fortney JA, Kigondu CS, Feldblum PJ, Kuyoh M, Allen MY, et al. Contraceptive use and HIV infection in Kenyan family planning clinic attenders. Int J STD AIDS 1996; 7:65–70.
    1. Ungchusak K, Rehle T, Thammapornpilap P, Spiegelman D, Brinkmann U, Siraprapasiri T. Determinants of HIV infection among female commercial sex workers in northeastern Thailand: results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:500–507.
    1. Wasserstein RL, Lazar NA. The ASA's statement on p-values: context, process, and purpose. Am Stat 2016; 70:129–133.
    1. McCoy SI, Ralph LJ, Padian NS, Minnis AM. Are hormonal contraceptive users more likely to misreport unprotected sex? Evidence from a biomarker validation study in Zimbabwe. AIDS Behav 2014; 18:2259–2264.
    1. Smit J, Gray A, McFadyen L, Zuma K. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa. BMC Health Serv Res 2001; 1:4.
    1. Morroni C, Myer L, Moss M, Hoffman M. Preferences between injectable contraceptive methods among South African women. Contraception 2006; 73:598–601.
    1. Grabowski MK, Gray RH, Makumbi F, Kagaayi J, Redd AD, Kigozi G, et al. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda. Lancet Glob Health 2015; 3:e478–e486.
    1. Borgdorff H, Verwijs MC, Wit FW, Tsivtsivadze E, Ndayisaba GF, Verhelst R, et al. The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in African sex workers. Sex Transm Dis 2015; 42:143–152.
    1. Egger M, Smith GD, Schneider M. In: Egger M, Smith GD, Altman DG. Systematic reviews of observational studies. BMJ Publishing Group, Systematic reviews in healthcare: meta-analysis in context. London:2001.
    1. Senn SJ. Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol 2009; 9:10.
    1. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998; 316:140–144.
    1. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797–808.
    1. Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG 2012; 119:1067–1073.
    1. Sokat KY, Armbruster B. Implications of switching away from injectable hormonal contraceptives on the HIV epidemic. Socioecon Plann Sci 2015; 52:1–9.
    1. Jain AK. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception 2012; 86:645–652.
    1. Jain AK. Erratum to: Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception 2013; 88:195.
    1. Martin HL, Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1053–1059.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera